^
Association details:
| Biomarker: | SLC34A2 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | upifitamab rilsodotin (XMT-1536) (Microtubule inhibitor, NaPi2b-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)
Published date:
08/01/2022
Excerpt:
More responders were seen in high NaPi2b expressing tumors: ORR of 44% (7/16) (95% CI: 20%-70%) and 32% (7/22) (95% CI: 14%-55%) for Group A and B, respectively….In this post-hoc analysis of a phase Ib study comparing the safety and efficacy of UpRi in treating recurrent ovarian cancer, lower doses were associated with at least similar efficacy and improved tolerability than higher doses.
DOI:
https://doi.org/10.1016/S0090-8258(22)01541-4
